13F Holdings
中文EN

CALC CalciMedica, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1534133 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY34.5%
TTM EPS YoY152.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-763.3%
ROA-103.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets70.4%
Debt / equity0.00x
Current ratio4.96x
Interest coverage-14.15x

Cash quality & payout

Operating cash flow / net income1.20x
Accruals ratio21.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$15.23M$14.48M$15.86M$8.35M$18.90M
SG&A expense$7.89M$9.73M$22.22M$5.84M$17.04M
Operating income-$23.12M-$24.20M-$38.08M-$14.19M-$35.95M
Interest expense$1.42M$0———
Pretax income-$29.56M-$13.70M———
Income tax$0$0$1,000$1,000—
Net income-$29.56M-$13.70M-$34.36M-$7.82M-$35.82M
EBITDA-$23.07M-$24.15M-$38.02M-$14.14M-$35.43M
EPS (basic)-1.97-1.22-7.66-111.16-1.69
EPS (diluted)-1.97-1.22-7.66-111.16-1.69
Weighted avg. shares (diluted)15.01M11.25M4.49M82,24521.20M
Banking
Noninterest income$713,000$1.01M———
Balance sheet
Cash & equivalents$11.52M$7.93M$5.53M$1.33M$13.36M
Short-term investments$1.50M$10.73M$5.71M$0$50.31M
Current assets$13.53M$19.66M$11.61M$1.73M$67.08M
PP&E, net$50,000$119,000$167,000$147,000$1.98M
Total assets$13.59M$19.79M$12.19M$3.35M$69.09M
Current liabilities$3.78M$3.68M$4.03M$4.78M$4.06M
Total liabilities$20.23M$5.38M$4.03M$12.58M$4.07M
Shareholders' equity-$6.64M$14.41M$8.16M-$71.30M-$63.99M
Shares outstanding3.09M13.48M5.75M84,16521.36M
Cash flow statement
Operating cash flow-$21.18M-$21.15M-$25.73M-$11.76M-$31.50M
Capital expenditure$28,000$8,000$78,000$4,000$488,000
Free cash flow-$21.21M-$21.15M-$25.81M-$11.76M-$31.99M
Investing cash flow$9.55M-$4.42M$8.88M-$4,000$10.75M
Financing cash flow$15.21M$27.97M$20.90M$8.48M$695,000
Depreciation & amortization$46,000$58,000$58,000$52,000$519,000
Stock-based compensation$2.97M$2.31M$12.04M$1.81M$5.38M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.